{"id":"placebo-pbo","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL1201131","moleculeType":"Small molecule","molecularWeight":"338.44"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is a non-therapeutic control agent administered in blinded clinical trials to establish baseline efficacy and safety profiles of investigational drugs. Any observed effects are attributable to the placebo effect—psychological and physiological responses to the expectation of treatment rather than pharmacological action. Placebos are essential for determining whether observed clinical benefits exceed those from natural disease progression or psychological factors.","oneSentence":"Placebo has no active pharmacological mechanism; it is an inert substance used as a control in clinical trials.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:22.216Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in phase 3 clinical trials (specific indication depends on the active comparator)"}]},"trialDetails":[{"nctId":"NCT03410992","phase":"PHASE3","title":"A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2018-02-05","conditions":"Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis","enrollment":435},{"nctId":"NCT07355062","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Veverimer for the Treatment of Metabolic Acidosis","status":"RECRUITING","sponsor":"Renibus Therapeutics, Inc.","startDate":"2026-01-13","conditions":"CKD, Metabolic Acidosis","enrollment":150},{"nctId":"NCT05063162","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOG-AD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2022-02-02","conditions":"Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOG-AD)","enrollment":104},{"nctId":"NCT04666610","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy","status":"ACTIVE_NOT_RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2021-07-29","conditions":"Childhood Absence Epilepsy, Juvenile Absence Epilepsy","enrollment":153},{"nctId":"NCT06617325","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus","status":"RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2024-11-21","conditions":"Systemic Lupus Erythematosus","enrollment":450},{"nctId":"NCT06333041","phase":"PHASE2, PHASE3","title":"Study of Cannabidiol in Sanfilippo Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2026-03-15","conditions":"Sanfilippo Syndrome, Mucopolysaccharidosis III","enrollment":35},{"nctId":"NCT04857983","phase":"PHASE2, PHASE3","title":"Memantine Augmentation of Targeted Cognitive Training in Schizophrenia","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2021-07-06","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":62},{"nctId":"NCT06222268","phase":"PHASE1","title":"Wayne State Warriors Marijuana Clinical Research Program: Cannabinoid Adjunct to Prolonged Exposure & Recovery","status":"NOT_YET_RECRUITING","sponsor":"Wayne State University","startDate":"2026-03","conditions":"PTSD, Post Traumatic Stress Disorder","enrollment":280},{"nctId":"NCT06970301","phase":"PHASE1","title":"A Study to Assess the Safety and Tolerability, and Pharmacokinetics of UCB0022 in Healthy Caucasian, Japanese, and Chinese Participants","status":"RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2025-04-28","conditions":"Healthy Study Participants","enrollment":32},{"nctId":"NCT03412747","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2018-01-26","conditions":"Chronic Plaque Psoriasis, Moderate to Severe Plaque Psoriasis","enrollment":478},{"nctId":"NCT03370133","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2017-12-06","conditions":"Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis","enrollment":567},{"nctId":"NCT03896581","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2019-03-28","conditions":"Psoriatic Arthritis","enrollment":400},{"nctId":"NCT03895203","phase":"PHASE3","title":"A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2019-04-03","conditions":"Psoriatic Arthritis","enrollment":852},{"nctId":"NCT06373146","phase":"PHASE2","title":"A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-04-24","conditions":"Obesity","enrollment":392},{"nctId":"NCT02604199","phase":"PHASE2","title":"A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-09","conditions":"Hepatitis B","enrollment":58},{"nctId":"NCT07161310","phase":"NA","title":"Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors","status":"RECRUITING","sponsor":"Goethe University","startDate":"2026-01-02","conditions":"Solid Cancer, Non-Small Cell Lung Cancer, Melanoma","enrollment":45},{"nctId":"NCT03703856","phase":"PHASE4","title":"Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Diego","startDate":"2019-01-31","conditions":"Alzheimer Disease","enrollment":53},{"nctId":"NCT03928743","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2019-04-25","conditions":"Ankylosing Spondylitis","enrollment":332},{"nctId":"NCT03928704","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2019-04-25","conditions":"Nonradiographic Axial Spondyloarthritis","enrollment":274},{"nctId":"NCT03971422","phase":"PHASE3","title":"A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2019-06-03","conditions":"Generalized Myasthenia Gravis","enrollment":200},{"nctId":"NCT03536884","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2018-06-13","conditions":"Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis","enrollment":743},{"nctId":"NCT05845645","phase":"PHASE1","title":"A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to Test Safety, Tolerability, and Pharmacokinetic (PK) of UCB0599 in Healthy Japanese and Chinese Participants in Part B","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2023-05-31","conditions":"Healthy Study Participants","enrollment":73},{"nctId":"NCT04232553","phase":"PHASE3","title":"A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2020-06-22","conditions":"Crohn's Disease","enrollment":996},{"nctId":"NCT05249556","phase":"PHASE3","title":"Double-blind, Randomized, Placebo-controlled Trial of Ganaxolone in CDKL5 Deficiency Patients 6 Months to Less Than 2 Years Old","status":"NOT_YET_RECRUITING","sponsor":"Immedica Pharma AB","startDate":"2026-06","conditions":"CDKL5 Deficiency Disorder","enrollment":20},{"nctId":"NCT04867642","phase":"PHASE1","title":"A Study to Test the Safety, Tolerability, and Blood Levels of UCB0022 in Healthy Participants and Participants With Parkinson's Disease","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2021-04-29","conditions":"Healthy Study Participants, Parkinson's Disease","enrollment":100},{"nctId":"NCT03923725","phase":"PHASE3","title":"A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs.","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2020-09-01","conditions":"Plasmodium Falciparum Malaria (Uncomplicated)","enrollment":2583},{"nctId":"NCT04242498","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2020-03-02","conditions":"Hidradenitis Suppurativa","enrollment":509},{"nctId":"NCT04242446","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2020-02-19","conditions":"Hidradenitis Suppurativa","enrollment":505},{"nctId":"NCT04880031","phase":"PHASE2","title":"A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension","status":"COMPLETED","sponsor":"Boston Pharmaceuticals","startDate":"2021-09-30","conditions":"Nonalcoholic Steatohepatitis (NASH)","enrollment":231},{"nctId":"NCT05262270","phase":"PHASE2","title":"Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2)","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2023-04-18","conditions":"Cocaine Use Disorder","enrollment":427},{"nctId":"NCT03524092","phase":"PHASE3","title":"A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-10-19","conditions":"Ulcerative Colitis","enrollment":1177},{"nctId":"NCT02069366","phase":"NA","title":"Cannabinoid Control of Fear Extinction Neural Circuits in Post-traumatic Stress Disorder","status":"COMPLETED","sponsor":"Wayne State University","startDate":"2014-11","conditions":"Post-Traumatic Stress Disorder","enrollment":86},{"nctId":"NCT04846829","phase":"EARLY_PHASE1","title":"Effects of Intravenous (IV) Citalopram Hydrochloride During Transcranial Magnetic Stimulation in Major Depressive Disorder (MDD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2017-04-24","conditions":"Major Depressive Disorder","enrollment":30},{"nctId":"NCT03288454","phase":"PHASE2","title":"Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT","status":"COMPLETED","sponsor":"Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.","startDate":"2017-08-30","conditions":"Healthy","enrollment":60},{"nctId":"NCT03172910","phase":"PHASE2","title":"Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT","status":"COMPLETED","sponsor":"Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.","startDate":"2017-05-08","conditions":"Healthy","enrollment":69},{"nctId":"NCT06408857","phase":"PHASE1","title":"Study To Evaluate Safety, Tolerability, and Pharmacokinetics of MAM01 in African Population","status":"RECRUITING","sponsor":"Gates Medical Research Institute","startDate":"2025-03-28","conditions":"Healthy Volunteers","enrollment":123},{"nctId":"NCT03008005","phase":"PHASE4","title":"Effects of Delta-9 Tetrahydrocannabinol (THC) on Retention of Memory for Fear Extinction Learning in PTSD: R61 Study","status":"COMPLETED","sponsor":"Wayne State University","startDate":"2017-06-01","conditions":"PostTraumatic Stress Disorder","enrollment":46},{"nctId":"NCT05634746","phase":"PHASE3","title":"24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3)","status":"COMPLETED","sponsor":"Ellodi Pharmaceuticals, LP","startDate":"2022-12-29","conditions":"Eosinophilic Esophagitis","enrollment":218},{"nctId":"NCT04544293","phase":"PHASE3","title":"Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Savara Inc.","startDate":"2021-05-19","conditions":"Autoimmune Pulmonary Alveolar Proteinosis","enrollment":164},{"nctId":"NCT05523167","phase":"PHASE2, PHASE3","title":"A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.","status":"ACTIVE_NOT_RECRUITING","sponsor":"argenx","startDate":"2022-10-12","conditions":"Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis","enrollment":265},{"nctId":"NCT05712694","phase":"PHASE3","title":"Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)","status":"RECRUITING","sponsor":"Polaris Group","startDate":"2023-11-29","conditions":"Soft Tissue Sarcoma","enrollment":300},{"nctId":"NCT04080427","phase":"PHASE1","title":"Effects of Delta9-tetrahydrocannabinol (THC) on Retention of Memory for Fear Extinction Learning in PTSD: R33 Study","status":"COMPLETED","sponsor":"Wayne State University","startDate":"2021-04-15","conditions":"Posttraumatic Stress Disorder","enrollment":102},{"nctId":"NCT03678753","phase":"PHASE3","title":"Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures","status":"COMPLETED","sponsor":"SK Life Science, Inc.","startDate":"2018-09-21","conditions":"Primary Generalized Epilepsy","enrollment":169},{"nctId":"NCT05594589","phase":"PHASE2","title":"A Study to Assess the Pharmacodynamics of Lemborexant in Korean Participants With Insomnia Disorder","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2022-11-30","conditions":"Sleep Initiation and Maintenance Disorders","enrollment":65},{"nctId":"NCT05643794","phase":"PHASE2","title":"A Proof-of-concept Study to Evaluate the Efficacy and Safety of Rozanolixizumab to Treat Adult Study Participants With Severe Fibromyalgia Syndrome","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2022-12-21","conditions":"Fibromyalgia","enrollment":63},{"nctId":"NCT06640517","phase":"PHASE3","title":"Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biocad","startDate":"2024-08-08","conditions":"Plaque Psoriasis","enrollment":140},{"nctId":"NCT05004987","phase":"PHASE4","title":"Aβ Dynamics in LLMD","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2022-02-04","conditions":"Alzheimer Disease, Major Depressive Disorder","enrollment":60},{"nctId":"NCT05004727","phase":"PHASE4","title":"Multi-Center PAMPA Study","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2022-02-16","conditions":"Psoriasis","enrollment":176},{"nctId":"NCT05269459","phase":"PHASE2","title":"Safety and Efficacy of Cannabidiol (CBD) for Symptoms of PTSD in Adults","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2022-12-01","conditions":"PTSD","enrollment":180},{"nctId":"NCT05066672","phase":"PHASE2","title":"Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression","status":"COMPLETED","sponsor":"Navitor Pharmaceuticals, Inc.","startDate":"2022-02-28","conditions":"Treatment Resistant Depression","enrollment":400},{"nctId":"NCT05011266","phase":"PHASE2, PHASE3","title":"Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder","status":"RECRUITING","sponsor":"New York State Psychiatric Institute","startDate":"2023-04-18","conditions":"Opioid-use Disorder","enrollment":180},{"nctId":"NCT04294667","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2020-08-12","conditions":"Systemic Lupus Erythematosus","enrollment":321},{"nctId":"NCT05855369","phase":"PHASE2, PHASE3","title":"Study of Chemosensory Enhancement Through Neuromodulation Training (SCENT for Long COVID)","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2023-10-02","conditions":"Smell Dysfunction, Olfactory Disorder, Long COVID","enrollment":180},{"nctId":"NCT04593784","phase":"PHASE2","title":"Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults","status":"TERMINATED","sponsor":"AMAG Pharmaceuticals, Inc.","startDate":"2021-10-13","conditions":"Healthy","enrollment":41},{"nctId":"NCT05447286","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of NYX-783 and Oxycodone DDI Study","status":"COMPLETED","sponsor":"Yale University","startDate":"2023-05-15","conditions":"Opioid Use Disorder","enrollment":9},{"nctId":"NCT03245437","phase":"PHASE4","title":"Target Engagement and Response to Oxytocin","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2018-01-04","conditions":"Schizophrenia","enrollment":120},{"nctId":"NCT05283304","phase":"PHASE2","title":"Monthly Injectable BUP for MA Use Disorder (MURB) Trial","status":"TERMINATED","sponsor":"Madhukar H. Trivedi, MD","startDate":"2023-03-24","conditions":"Methamphetamine-dependence","enrollment":18},{"nctId":"NCT05020249","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2021-09-27","conditions":"Moderate to Severe Plaque Psoriasis","enrollment":47},{"nctId":"NCT05738746","phase":"NA","title":"The Efficacy of Pasteurised Akkermansia Muciniphila in Healthy Medical Workers","status":"COMPLETED","sponsor":"Pomeranian Medical University Szczecin","startDate":"2023-10-24","conditions":"Stress, Healthy, Dietary Supplement","enrollment":202},{"nctId":"NCT05536726","phase":"PHASE3","title":"A Phase 3 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","startDate":"2023-01-07","conditions":"Psoriasis","enrollment":458},{"nctId":"NCT06087406","phase":"PHASE1","title":"A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis","status":"TERMINATED","sponsor":"IGM Biosciences, Inc.","startDate":"2023-03-15","conditions":"Rheumatoid Arthritis, Arthritis, Rheumatoid, Arthritis","enrollment":33},{"nctId":"NCT03398148","phase":"PHASE2, PHASE3","title":"A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-03-07","conditions":"Ulcerative Colitis (UC)","enrollment":1558},{"nctId":"NCT01451203","phase":"PHASE3","title":"Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-10-11","conditions":"Rheumatoid Arthritis","enrollment":319},{"nctId":"NCT04078178","phase":"NA","title":"Crossover Trial for Nicotinamide Riboside in Subjective Cognitive Decline and Mild Cognitive Impairment","status":"COMPLETED","sponsor":"Steven E Arnold, MD","startDate":"2020-10-30","conditions":"Cognition Disorders in Old Age, Mild Cognitive Impairment, Cognitive Decline","enrollment":61},{"nctId":"NCT06345703","phase":"PHASE1","title":"First-into-human Study of NS-136 in Healthy Subjects","status":"RECRUITING","sponsor":"NeuShen Therapeutics","startDate":"2024-04-30","conditions":"Healthy Subjects","enrollment":76},{"nctId":"NCT06538558","phase":"PHASE1","title":"Study to Assess the Use of Tezampanel for Opioid Withdrawal Syndrome in Treatment-Seeking Patients With Opioid Use Disorder","status":"RECRUITING","sponsor":"Proniras Corporation","startDate":"2024-10-16","conditions":"Opioid Use Disorder","enrollment":40},{"nctId":"NCT01107496","phase":"PHASE1, PHASE2","title":"Evaluation of Immediate-Release Viloxazine in Adults With ADHD","status":"COMPLETED","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2010-06","conditions":"Attention-Deficit/Hyperactivity Disorder (ADHD)","enrollment":52},{"nctId":"NCT05174416","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM","status":"COMPLETED","sponsor":"LianBio LLC","startDate":"2022-01-04","conditions":"Obstructive Hypertrophic Cardiomyopathy","enrollment":81},{"nctId":"NCT05097079","phase":"PHASE3","title":"Efficacy and Safety Study of MYOBLOC in the Treatment of Sialorrhea in Pediatric Subjects","status":"WITHDRAWN","sponsor":"Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC","startDate":"2021-11","conditions":"Sialorrhea","enrollment":""},{"nctId":"NCT04913610","phase":"PHASE2","title":"Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection","status":"TERMINATED","sponsor":"AbbVie","startDate":"2021-05-22","conditions":"Onchocerciasis","enrollment":153},{"nctId":"NCT00700661","phase":"PHASE3","title":"A Study of MK0476 in the Treatment of Asthma Patients Aged 2-5 Years (0476-907)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-01","conditions":"Asthma","enrollment":500},{"nctId":"NCT00200902","phase":"PHASE4","title":"Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2005-08","conditions":"Depression","enrollment":88},{"nctId":"NCT04677504","phase":"PHASE2","title":"A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-02-23","conditions":"Biliary Tract Cancer","enrollment":162},{"nctId":"NCT00447603","phase":"PHASE3","title":"A Study of Losartan Compared to Losartan/HCTZ in Pediatric Patients With Hypertension (0954A-327)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2007-05-24","conditions":"Hypertension","enrollment":40},{"nctId":"NCT00535405","phase":"PHASE3","title":"A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-11","conditions":"Hypercholesterolemia","enrollment":1289},{"nctId":"NCT00271817","phase":"PHASE3","title":"To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-12","conditions":"Hypercholesterolemia","enrollment":1220},{"nctId":"NCT00276458","phase":"PHASE3","title":"To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 20 mg (0653-079)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-02","conditions":"Hypercholesterolemia","enrollment":196},{"nctId":"NCT00534976","phase":"PHASE4","title":"The Effect of Montelukast on Difficulty in Breathing After Exercise in Pediatric Patients (MK0476-377)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-02","conditions":"Exercise-induced Bronchoconstriction (EIB)","enrollment":364},{"nctId":"NCT00284856","phase":"PHASE3","title":"Montelukast Asthmatic Smoker Study (0476-332)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-05","conditions":"Asthma","enrollment":1640},{"nctId":"NCT00337675","phase":"PHASE3","title":"Intermittent and Daily Dosing for Episodic (Periodic) Asthma (0476-302)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-10","conditions":"Asthma","enrollment":1771},{"nctId":"NCT00117338","phase":"PHASE3","title":"A Study of an Intravenous Drug in Pediatric Patients With Acute Asthma (0476-301)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-07","conditions":"Asthma","enrollment":276},{"nctId":"NCT00664937","phase":"PHASE1","title":"Exercise Induced Bronchoconstriction (0476-359)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-05","conditions":"Asthma, Exercise-induced","enrollment":24},{"nctId":"NCT04622007","phase":"PHASE2","title":"Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Effector Therapeutics","startDate":"2021-06-02","conditions":"Non-small Cell Lung Cancer","enrollment":68},{"nctId":"NCT00516737","phase":"PHASE3","title":"Study to Test Rizatriptan in the Early Treatment of Acute Migraine (0462-081)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-10-03","conditions":"Migraine","enrollment":207},{"nctId":"NCT03980184","phase":"PHASE2","title":"Guanfacine to Improve Substance Use Outcomes in Women","status":"COMPLETED","sponsor":"Yale University","startDate":"2019-11-01","conditions":"Substance Use Disorders","enrollment":74},{"nctId":"NCT03939104","phase":"PHASE3","title":"A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combinations of 2 Anti-malarial Drugs (Asia)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2021-06-30","conditions":"Plasmodium Falciparum Malaria (Uncomplicated)","enrollment":103},{"nctId":"NCT04828343","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Rozanolixizumab Administered Subcutaneously Via Manual Push Versus Syringe Driver to Healthy Participants","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2021-04-22","conditions":"Healthy Study Participants","enrollment":32},{"nctId":"NCT00150709","phase":"PHASE3","title":"A Study Of The Safety And Efficacy Of Levetiracetam (Keppra®) (Ucb L059) In Children With Epilepsy","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"1998-01-26","conditions":"Epilepsy, Partial","enrollment":223},{"nctId":"NCT05892276","phase":"NA","title":"Effects of CBD Oil on Memory Reconsolidation and Trauma-Related Symptoms","status":"WITHDRAWN","sponsor":"University of Texas at Austin","startDate":"2024-08-31","conditions":"Posttraumatic Stress Disorder","enrollment":""},{"nctId":"NCT06169891","phase":"PHASE3","title":"A Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout","status":"UNKNOWN","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","startDate":"2023-12","conditions":"Acute Gout","enrollment":500},{"nctId":"NCT04659161","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2)","status":"COMPLETED","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2020-12-16","conditions":"Schizophrenia, Schizophrenia; Psychosis","enrollment":252},{"nctId":"NCT04802746","phase":"PHASE1","title":"A Study to Assess the Pulmonary Safety of Staccato Alprazolam in Healthy Study Participants and in Study Participants With Mild Asthma","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2021-03-09","conditions":"Healthy Study Participants, Participants With Mild Asthma","enrollment":78},{"nctId":"NCT02563769","phase":"PHASE1","title":"Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study","status":"COMPLETED","sponsor":"Temple University","startDate":"2016-10-24","conditions":"Cocaine Dependence, Cocaine Addiction, Cocaine Abuse","enrollment":10},{"nctId":"NCT04632381","phase":"PHASE1","title":"Intravenous Zotatifin in Adults With Mild or Moderate COVID-19","status":"COMPLETED","sponsor":"Effector Therapeutics","startDate":"2021-07-01","conditions":"Corona Virus Infection","enrollment":36},{"nctId":"NCT05163717","phase":"PHASE2","title":"INP105 Proof-of-concept Study for the Acute Treatment of Agitation in Adolescents and Young Adults With ASD","status":"TERMINATED","sponsor":"Impel Pharmaceuticals","startDate":"2022-06-23","conditions":"Agitation in Adolescents and Young Adults With ASD","enrollment":8},{"nctId":"NCT05083312","phase":"PHASE3","title":"Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial","status":"COMPLETED","sponsor":"Ellodi Pharmaceuticals, LP","startDate":"2021-09-30","conditions":"Eosinophilic Esophagitis","enrollment":6},{"nctId":"NCT04411914","phase":"PHASE1","title":"Pharmaco-Magnetic Resonance Spectroscopy (MRS) Study of Clavulanic Acid","status":"COMPLETED","sponsor":"Temple University","startDate":"2020-09-01","conditions":"Cocaine Dependence","enrollment":13},{"nctId":"NCT04281108","phase":"PHASE3","title":"Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2)","status":"COMPLETED","sponsor":"Ellodi Pharmaceuticals, LP","startDate":"2020-01-30","conditions":"Eosinophilic Esophagitis","enrollment":143},{"nctId":"NCT03811847","phase":"PHASE4","title":"A Pilot of Methylphenidate in Mild Cognitive Impairment and Dementia Participants.","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2019-11-01","conditions":"Alzheimer Dementia","enrollment":11},{"nctId":"NCT04006925","phase":"PHASE4","title":"Treatment of REM Sleep Behavior Disorder (RBD) With Sodium Oxybate","status":"COMPLETED","sponsor":"Stanford University","startDate":"2019-09-10","conditions":"REM Sleep Behavior Disorder, Parkinson Disease","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":544,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo (PBO)","genericName":"Placebo (PBO)","companyName":"Ridgeback Biotherapeutics, LP","companyId":"ridgeback-biotherapeutics-lp","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo has no active pharmacological mechanism; it is an inert substance used as a control in clinical trials. Used for Control arm in phase 3 clinical trials (specific indication depends on the active comparator).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}